Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study.
OBJECTIVE
There is an ongoing debate regarding doses of antipsychotic in stable schizophrenia patients. This French pilot study was undertaken to estimate two strategies of treatment with olanzapine in stable phase - maintenance of the acute dose or dose reduction.


METHODS
6 months open, randomized trial comparing two strategies of treatment with olanzapine in 97 schizophrenia stabilized outpatients.


RESULTS
Mean daily doses at 6 months in the olanzapine full dose (OFD) and reduction dose (ORD) groups were respectively 18.1 mg and 13.3 mg. 4 patients (8%) relapsed in the ORD group versus 3 (6%) in the OFD group. A secondary analysis reflecting more real life setting showed a numerically higher rate of relapse in the dose reduction group (20% versus 10%).


CONCLUSIONS
These results suggest that maintenance treatment with olanzapine, beyond 4 months, with the same dose that was effective acutely could be useful to prevent new psychiatric hospitalization.
CMME, Hôpital St Anne, Université Paris V, France.
Frédéric
F
Rouillon
Florence
F
Chartier
Isabelle
I
Gasquet
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004637:Emergency Services, Psychiatric; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010865:Pilot Projects; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D055502:Secondary Prevention
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine